Header Logo

Connection

JOHN KIRKWOOD to Randomized Controlled Trials as Topic

Back to Details
This is a "connection" page, showing publications JOHN KIRKWOOD has written about Randomized Controlled Trials as Topic.
JOHN KIRKWOOD
Connection Strength
0.670
Randomized Controlled Trials as Topic
  1. Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C?melanoma is removed by surgery. Future Oncol. 2024 May; 20(15):959-968.
    View in: PubMed
    Score: 0.134
  2. An updated analysis of 4 randomized ECOG trials of high-dose interferon in the adjuvant treatment of melanoma. Cancer. 2019 09 01; 125(17):3013-3024.
    View in: PubMed
    Score: 0.096
  3. Prospective Validation of Molecular Prognostic Markers in Cutaneous Melanoma: A Correlative Analysis of E1690. Clin Cancer Res. 2017 Nov 15; 23(22):6888-6892.
    View in: PubMed
    Score: 0.085
  4. Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncol. 2014 Mar; 15(3):297-304.
    View in: PubMed
    Score: 0.067
  5. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med. 2008 Oct 27; 6:62.
    View in: PubMed
    Score: 0.046
  6. Adjuvant therapy of melanoma. Semin Cutan Med Surg. 2003 Mar; 22(1):55-67.
    View in: PubMed
    Score: 0.031
  7. An update on adjuvant interferon for melanoma. Cancer Control. 2002 Jan-Feb; 9(1):16-21.
    View in: PubMed
    Score: 0.029
  8. Systemic Therapy for Melanoma: ASCO Guideline. J Clin Oncol. 2020 11 20; 38(33):3947-3970.
    View in: PubMed
    Score: 0.025
  9. KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma. Future Oncol. 2020 Jan; 16(3):4429-4438.
    View in: PubMed
    Score: 0.025
  10. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol. 2018 03; 19(3):310-322.
    View in: PubMed
    Score: 0.022
  11. Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II-III Melanoma Adjuvant Therapy. J Natl Cancer Inst. 2018 01 01; 110(1).
    View in: PubMed
    Score: 0.022
  12. Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma. J Clin Oncol. 2017 Dec 01; 35(34):3815-3822.
    View in: PubMed
    Score: 0.021
  13. Adjuvant interferon-a for the treatment of high-risk melanoma: An individual patient data meta-analysis. Eur J Cancer. 2017 09; 82:171-183.
    View in: PubMed
    Score: 0.021
  14. Future perspectives in melanoma research. Meeting report from the "Melanoma research: a bridge from Naples to the World. Napoli, December 5th-6th 2011". J Transl Med. 2012 Jul 04; 10:83.
    View in: PubMed
    Score: 0.015
  15. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011; 16(1):5-24.
    View in: PubMed
    Score: 0.013
  16. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. Arch Ophthalmol. 2005 Dec; 123(12):1639-43.
    View in: PubMed
    Score: 0.009
  17. Present status and future prospects for adjuvant therapy of melanoma: time to build upon the foundation of high-dose interferon alfa-2b. J Clin Oncol. 2004 Jan 01; 22(1):11-4.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.